Herpes simplex type-2 (HSV-2) infection has been consistently identified as a risk factor for HIV acquisition, with 2-5-fold increased risk of HIV acquisition in HSV-2 seropositive persons. A proofof- concept, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of HSV-2 suppression among HSV-2+ persons at high risk of HIV was initiated in 2001 among heterosexual women in Zambia, Zimbabwe, and South Africa and men who have sex with men (MSM) in the U.S. and Peru. With RO1 and HPTN funding, the trial has enrolled 1430 persons. This application requests funds to complete the trial due to delays and new operational and regulatory requirements. The hypothesis is that standard doses of daily acyclovir 400 mg bid will reduce HIV incidence by 50% in heterosexual women and MSM by decreasing rates of clinical and subclinical HSV-2 reactivation.
Specific aims are: 1) To measure the efficacy of daily generic acyclovir 400 mg bid in preventing HIV acquisition among HSV-2 seropositive, HIV-negative heterosexual women and MSM at high risk of HIV infection; 2) To determine the effect of twice daily acyclovir suppressive therapy on reducing the frequency of genital ulcers and subclinical HSV-2 reactivation among HSV-2 seropositive, HIV-negative persons; and 3) To assess adherence with twice daily acyclovir suppressive therapy among HSV-2 seropositive, HIVnegative persons. With recent data strengthening the association between HSV-2 reactivation, higher plasma HIV RNA levels, and faster HIV disease progression, a fourth aim has been added: 4) To measure the efficacy of twice daily acyclovir suppressive therapy on HIV plasma viral RNA levels during the first 6 months after HIV infection. Hypothesis: Acyclovir 400 mgbid will lower HIV RNA at setpoint, potentially resulting in slower disease progression and lower infectivity to partners. The trial will enroll 2820 (1410/arm) African women and MSM with 18 months follow-up for HIV acquisition. Implementation has been excellent (92% follow-up at 6 months), high' adherence to study drug (93.4% of visits reported 75% of study drug taken); and no serious adverse events related to study drug. Overall HIV acquisition rate has been 2.5% (95% Cl 0.9 to 4.1), indicating enrollment of high risk persons and that the trial will answer the study question. Given high HSV-2 infection rates globally in persons at risk for HIV, this approach could have great public health impact by providing a safe, acceptable and cost-effective method to reduce HIV susceptibility. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI052054-04S1
Application #
7262395
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Chow, Grace C
Project Start
2002-07-01
Project End
2008-07-31
Budget Start
2005-10-01
Budget End
2006-07-31
Support Year
4
Fiscal Year
2006
Total Cost
$1,482,575
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Koelle, David M; Norberg, Peter; Fitzgibbon, Matthew P et al. (2017) Worldwide circulation of HSV-2?×?HSV-1 recombinant strains. Sci Rep 7:44084
Baisley, Kathy; Baeten, Jared M; Hughes, James P et al. (2013) Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reporting. AIDS Behav 17:3108-19
Laeyendecker, Oliver; Kulich, Michal; Donnell, Deborah et al. (2013) Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One 8:e78818
Baeten, Jared M; Reid, Stewart E; Delany-Moretlwe, Sinead et al. (2012) Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. Sex Transm Dis 39:21-4
Sánchez, Jorge; Sal Y Rosas, Victor G; Hughes, James P et al. (2011) Male circumcision and risk of HIV acquisition among MSM. AIDS 25:519-23
Curlin, Marcel E; Cassis-Ghavami, Farah; Magaret, Amalia S et al. (2011) Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 25:153-8
Jacob, Shevin T; Baeten, Jared M; Hughes, James P et al. (2011) A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav 15:897-904
Watson-Jones, Deborah; Wald, Anna; Celum, Connie et al. (2010) Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 48:3496-503
Kim, H Nina; Wang, Jing; Hughes, James et al. (2010) Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 202:734-8
Fuchs, Jonathan; Celum, Connie; Wang, Jing et al. (2010) Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis 201:1164-8

Showing the most recent 10 out of 14 publications